HUE028870T2 - New compounds with inhibitory effect of diacylglycerol acyltransferase - Google Patents

New compounds with inhibitory effect of diacylglycerol acyltransferase Download PDF

Info

Publication number
HUE028870T2
HUE028870T2 HUE12789931A HUE12789931A HUE028870T2 HU E028870 T2 HUE028870 T2 HU E028870T2 HU E12789931 A HUE12789931 A HU E12789931A HU E12789931 A HUE12789931 A HU E12789931A HU E028870 T2 HUE028870 T2 HU E028870T2
Authority
HU
Hungary
Prior art keywords
amino
pyrimido
oxazepin
oxo
mmol
Prior art date
Application number
HUE12789931A
Other languages
English (en)
Hungarian (hu)
Inventor
Donghui Qin
Mui Cheung
Hemant Joshi
Raghuram Tangirala
Sridhar Reddy Bethi
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of HUE028870T2 publication Critical patent/HUE028870T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HUE12789931A 2011-05-20 2012-05-18 New compounds with inhibitory effect of diacylglycerol acyltransferase HUE028870T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1452DE2011 2011-05-20
US201161503728P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
HUE028870T2 true HUE028870T2 (en) 2017-01-30

Family

ID=47217645

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12789931A HUE028870T2 (en) 2011-05-20 2012-05-18 New compounds with inhibitory effect of diacylglycerol acyltransferase

Country Status (34)

Country Link
US (4) US8859536B2 (enExample)
EP (1) EP2710013B1 (enExample)
JP (1) JP5844456B2 (enExample)
KR (1) KR101919080B1 (enExample)
CN (1) CN103703009B (enExample)
AU (1) AU2012259044B2 (enExample)
BR (1) BR112013029935B1 (enExample)
CA (1) CA2836669C (enExample)
CO (1) CO6811855A2 (enExample)
CR (1) CR20130602A (enExample)
CY (1) CY1118188T1 (enExample)
DK (1) DK2710013T3 (enExample)
DO (1) DOP2013000272A (enExample)
EA (1) EA023030B1 (enExample)
ES (1) ES2588748T3 (enExample)
HR (1) HRP20161089T1 (enExample)
HU (1) HUE028870T2 (enExample)
IL (1) IL229488A (enExample)
LT (1) LT2710013T (enExample)
MA (1) MA35185B1 (enExample)
ME (1) ME02479B (enExample)
MX (1) MX346494B (enExample)
MY (1) MY184553A (enExample)
PE (1) PE20141204A1 (enExample)
PH (1) PH12013502401A1 (enExample)
PL (1) PL2710013T3 (enExample)
PT (1) PT2710013T (enExample)
RS (1) RS55006B1 (enExample)
SG (1) SG195044A1 (enExample)
SI (1) SI2710013T1 (enExample)
SM (1) SMT201600328B (enExample)
UA (1) UA111360C2 (enExample)
WO (1) WO2012162129A1 (enExample)
ZA (1) ZA201308664B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101919080B1 (ko) 2011-05-20 2018-11-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
EP3492474B1 (en) 2012-11-23 2021-08-11 GlaxoSmithKline LLC Intermediates used in the production of diacylglycerol acyltransferase inhibitors
WO2014081996A1 (en) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
WO2015049668A1 (en) 2013-10-03 2015-04-09 Glaxosmithkline Intellectual Property (No.2) Limited Novel compound as a diacylglycerol acyltransferase inhibitor
WO2015049667A1 (en) 2013-10-03 2015-04-09 Glaxosmithkline Intellectual Property (No.2) Limited Novel compound as a diacylglycerol acyltransferase inhibitor
CN103880757B (zh) * 2014-04-15 2016-02-24 上海毕得医药科技有限公司 一种5-羟基嘧啶-2-羧酸的合成方法
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
CN105732461A (zh) * 2016-02-03 2016-07-06 常州工程职业技术学院 5-甲氧基-6-卤代吲哚的制备方法
CN106083707B (zh) * 2016-06-01 2018-10-26 温州大学 一种非对称杂芳基硫醚的合成方法
CN107619932B (zh) * 2016-07-15 2020-08-07 中国科学院上海有机化学研究所 一种萃取组合物、萃取体系及其应用
CN107619928B (zh) * 2016-07-15 2020-08-07 中国科学院上海有机化学研究所 一种萃取组合物、萃取体系及其应用
RU2706655C1 (ru) * 2019-01-28 2019-11-19 Акционерное общество "Гознак" (АО "Гознак") Полимерсодержащее композиционное защищенное изделие
CN117603242B (zh) * 2023-11-30 2026-08-11 沧州普瑞东方科技有限公司 一种反式-1-乙氧乙烯基-2-硼酸频那醇酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090036425A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
KR101685718B1 (ko) * 2008-12-19 2016-12-12 제넨테크, 인크. 헤테로시클릭 화합물 및 사용 방법
TW201038580A (en) * 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
JP2012520887A (ja) * 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
ES2513915T3 (es) 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
KR101919080B1 (ko) 2011-05-20 2018-11-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors

Also Published As

Publication number Publication date
CN103703009A (zh) 2014-04-02
AU2012259044B2 (en) 2015-09-17
US20160200736A1 (en) 2016-07-14
US9540400B2 (en) 2017-01-10
AU2012259044A1 (en) 2013-12-12
SG195044A1 (en) 2013-12-30
PT2710013T (pt) 2016-09-28
SI2710013T1 (sl) 2016-10-28
MX2013013566A (es) 2014-01-08
CO6811855A2 (es) 2013-12-16
DOP2013000272A (es) 2014-05-15
KR20140045415A (ko) 2014-04-16
IL229488A (en) 2016-04-21
MA35185B1 (fr) 2014-06-02
UA111360C2 (uk) 2016-04-25
US8859536B2 (en) 2014-10-14
BR112013029935A2 (pt) 2016-09-20
HRP20161089T1 (hr) 2016-10-21
NZ617991A (en) 2015-06-26
US9040517B2 (en) 2015-05-26
ES2588748T3 (es) 2016-11-04
CA2836669A1 (en) 2012-11-29
CA2836669C (en) 2019-03-19
HK1194738A1 (zh) 2014-10-24
IL229488A0 (en) 2014-01-30
ME02479B (me) 2017-02-20
EP2710013B1 (en) 2016-06-29
US9273069B2 (en) 2016-03-01
JP2014517839A (ja) 2014-07-24
SMT201600328B (it) 2016-11-10
EP2710013A1 (en) 2014-03-26
WO2012162129A1 (en) 2012-11-29
EA201391737A1 (ru) 2014-04-30
RS55006B1 (sr) 2016-11-30
KR101919080B1 (ko) 2018-11-16
LT2710013T (lt) 2016-09-12
PE20141204A1 (es) 2014-10-05
PH12013502401A1 (en) 2015-10-07
MX346494B (es) 2017-03-21
JP5844456B2 (ja) 2016-01-20
ZA201308664B (en) 2015-02-25
MY184553A (en) 2021-04-02
BR112013029935B1 (pt) 2020-12-15
CN103703009B (zh) 2016-08-17
DK2710013T3 (en) 2016-09-26
EA023030B1 (ru) 2016-04-29
PL2710013T3 (pl) 2017-08-31
EP2710013A4 (en) 2014-11-05
CY1118188T1 (el) 2017-06-28
US20150225425A1 (en) 2015-08-13
CR20130602A (es) 2014-08-13
US20140080809A1 (en) 2014-03-20
US20140378434A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
DK2710013T3 (en) New compounds such as diacylglycerol-acyltransferase inhibitors
US9505785B2 (en) Pyridone and aza-pyridone compounds and methods of use
WO2024243025A1 (en) Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions
CA3103055A1 (en) Erk inhibitor and use thereof
TW200951134A (en) Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-A]pyrimidines, methods for preparation and uses thereof
TW201121966A (en) Fused heterocyclic compounds as orexin receptor modulators
KR20120089463A (ko) 헤테로시클릭 옥심 화합물
TWI758325B (zh) 7-經取代之1-芳基萘啶-3-甲醯胺及其用途
TW202214634A (zh) 雜環化合物及其衍生物
CN102548995A (zh) 杂环腙化合物以及它们治疗癌症和炎症的用途
AU2013347843A1 (en) Novel compounds as diacylglycerol acyltransferase inhibitors
HK1194738B (en) Novel compounds as diacylglycerol acyltransferase inhibitors
NZ617991B2 (en) Novel compounds as diacylglycerol acyltransferase inhibitors
CN102574853A (zh) 杂环肟化合物